A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
A phase 3 trial of Anitocabtagene autoleucel, Cyclophosphamide, Fludarabine in multiple myeloma, run by Kite, A Gilead Company, active and no longer recruiting.
Overview
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06413498 by Kite, A Gilead Company, with 452 participants enrolled, started 2024-08-23 and due to reach its primary completion in 2028-07. Interventions recorded: Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialiMMagine-1
- TrialPhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.